ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint745,194 companies indexed · Last updated: today
DirectoryBusiness & Technical ServicesResearch & DevelopmentGenevaiOnctura SA
iOnctura SA Logo
Verified· 3 sources

iOnctura SA

Summary

About the company

The core activity of iOnctura is the development of cancer drugs, particularly in oncology immunotherapy, with a focus on solid tumors, uveal melanoma and other types of cancer.

AI-generated
Offering

Products & services

Industry:Research & DevelopmentPharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered6
Oncology small-molecule development
Oncology small-molecule programs against hard-to-treat, often neglected cancer types; focus on precisely targeted, orally dosed therapeutics with low toxicity.
Roginolisib (IOA-244)
Orally dosed PI3Kδ inhibitor in clinical development for uveal melanoma, NSCLC, myelofibrosis, CLL and PTCL; studied as monotherapy and in combination.
Cambritaxestat (IOA-289)
Orally dosed autotaxin inhibitor in clinical development for pancreatic and liver malignancies; studied in combination with chemotherapy.
IOA-359
Small molecule as a TGF-β signalling pathway inhibitor in development for solid tumors; designed for combination therapies against tumor resistance.
Clinical trials in oncology
Clinical trials in uveal melanoma, pancreatic cancer, NSCLC, myelofibrosis, CLL and PTCL with safety, efficacy and biomarker endpoints.
Precision oncology research
Research on first-in-class mechanisms at the tumor–stroma–immune interface; development of data-driven combination therapies against resistance mechanisms.
Press

Media

October 22, 2025Media
Promising results in oncology research
startupticker.ch
July 3, 2025Media
Startups and support organisations strengethen their leadership
startupticker.ch
July 14, 2020Media
iOnctura extends series A round to €20 million
startupticker.ch
Comparisons

iOnctura SA in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank iOnctura SA by reviews, experience and specialisations.

Is this your company?

Claim the company profile of iOnctura SA to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Avenue de Sécheron 15
1202 Geneva

At a glance

Legal form
Corporation
UID
CHE-160.748.717
Founded
2017 · 9 years
Last commercial register change
March 19, 2026
Employees
21 to 50

Knowledge

No knowledge articles yet

Once iOnctura SA has claimed this profile, we'll publish editorial articles and case studies here together.

Get started

Similar companies

DF
Drugs for Neglected Diseases initiative (DNDi)
Geneva
FE
Fondation EspeRare
Geneva
FP
Fondation pour l'institut de hautes études internationales et du développement
Geneva
DS
Dandelion Science Sàrl
Geneva
DA
Davos Alzheimer's Collaborative (Genève)
Geneva
DP
DRK Pharma Solutions SÀRL
Vandoeuvres
FC
Fondation CanSearCH
Geneva
TI
Triskel INTEGRATED SERVICES SA
Le Grand-Saconnex